Sustained virological response · patients on HD with HCV infection
Standard interferon showed no clear difference in sustained virological response 6 months after stopping treatment compared with placebo or control (moderate certainty).
1 finding from 1 review
Treatment discontinuation · patients on HD with HCV infection
Standard interferon showed no clear difference in treatment discontinuation compared with placebo or control (moderate certainty).
1 finding from 1 review
Adverse events · patients on HD with HCV infection
Standard interferon showed no clear difference in adverse events compared with placebo or control (moderate certainty).
1 finding from 1 review
Death · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relapse · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Sustained virological response · patients on HD with HCV infection
It is very uncertain whether pegylated interferon + ribavirin (24 weeks) + initial telepravir (12… changes sustained virological response compared with pegylated interferon (48 weeks) + initial telepravir (12 weeks) +… (very low certainty).
1 finding from 1 review
End‐of‐treatment response · patients on HD with HCV infection
It is very uncertain whether pegylated interferon + ribavirin (24 weeks) + initial telepravir (12… changes end‐of‐treatment response compared with pegylated interferon (48 weeks) + initial telepravir (12 weeks) +… (very low certainty).
1 finding from 1 review
Treatment discontinuation · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Pegylated interferon beta‐1a (Direct evidence; 1 RCT; 1512 participants) · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…
The intervention may leads to lower pegylated interferon beta‐1a (Direct evidence; 1 RCT; 1512… (low certainty).
1 finding from 1 review
Intervention not reported
Interferon beta 1a‐1b No direct evidence · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
It is very uncertain whether the intervention changes interferon beta 1a‐1b No direct evidence (very low certainty).
1 finding from 1 review
RR 1.21 [0.66, 2.19]
1 participants
Very low
Intervention not reported
Interferon beta‐1b (Betaferon) (Direct evidence; 1 RCT; 372 participants) · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention may leads to lower interferon beta‐1b (Betaferon) (Direct evidence; 1 RCT; 372… (low certainty).
1 finding from 1 review
Intervention not reported
Interferon beta‐1a (Avonex, Rebif) (Direct evidence; 3 RCTs; 1629 participants) · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention probably leads to lower interferon beta‐1a (Avonex, Rebif) (Direct evidence; 3 RCTs; 1629… (moderate certainty).
1 finding from 1 review
RR 0.84 [0.78, 0.91]
1 study · 3 participants
Moderate
Intervention not reported
Interferon beta 1a‐1b No direct evidence · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
It is very uncertain whether the intervention changes interferon beta 1a‐1b No direct evidence (very low certainty).
1 finding from 1 review
RR 3.19 [0.31, 33.21]
1 participants
Very low
Intervention not reported
Interferon beta‐1b (Betaferon) (Direct evidence; 1 RCT; 372 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention may leads to lower interferon beta‐1b (Betaferon) (Direct evidence; 1 RCT; 372… (low certainty).
1 finding from 1 review
Intervention not reported
Interferon beta‐1a (Avonex, Rebif) (Direct evidence; 2 RCTs; 1069 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention showed no clear difference in interferon beta‐1a (Avonex, Rebif) (Direct evidence; 2 RCTs; 1069… (low certainty).
1 finding from 1 review
RR 0.92 [0.73, 1.16]
1 study · 2 participants
Low
Intervention not reported
Interferon beta 1a‐1b No direct evidence · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
It is very uncertain whether the intervention changes interferon beta 1a‐1b No direct evidence (very low certainty).
1 finding from 1 review
OR 3.02 [0.27, 33.65]
1 participants
Very low
Intervention not reported
Interferon beta‐1b (Direct evidence; 1 RCT; 372 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention may leads to higher interferon beta‐1b (Direct evidence; 1 RCT; 372 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Interferon beta‐1a (Direct evidence; 2 RCTs; 1457 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention showed no clear difference in interferon beta‐1a (Direct evidence; 2 RCTs; 1457 participants) (moderate certainty).
1 finding from 1 review
OR 1.48 [0.99, 2.2]
1 study · 2 participants
Moderate
Intervention not reported
Pegylated interferon beta‐1a (Direct evidence; 1 RCT; 1512 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
It is very uncertain whether the intervention changes pegylated interferon beta‐1a (Direct evidence; 1 RCT; 1512… (very low certainty).
1 finding from 1 review